الفهرس 
Multiple MyelomaOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
ABSTRACT
Background: Multiple myeloma is characterized by the proliferation of malignant plasma cells within the bone marrow, which produce an abnormal monoclonal paraprotein and evidence of end organ damage. Multiple myeloma is one of the widespread cancer diseases, as it is the second most common blood cancer, and it is also one of the diseases that is difficult to follow up accurately, especially when trying to know the possibilities of relapse after treatment proactively, and for this reason, the need for ways to follow up patients with multiple myeloma after treatment emerged proactively. Accurate evaluation of the depth of response to treatment, especially post-treatment with an autologous bone marrow transplant.
Aim of the Work: to measure CRBN in MM patients post autologous stem cell transplantation to determine its prognostic impact, to do correlation with other prognostic factors & to detect its influence on maintenance treatment response.
Patients and Methods: To elucidate this aim twenty Newly diagnosed transplant eligible MM patients (NDMMET) were included in the study. All patients received the same treatment; induction by VCD for 6 cycles (28 days-cycle) until CR/VGPR. All patients underwent assessment of Serum CRBN post ASCT to assess the response and to check for any sign of relapse. MM workup was done to all patients involving bone marrow aspiration and bone marrow biopsy plus serum and urine protein immunofixation with free light chain assay in addition to routine methods for diagnosis. Diagnosis and response evaluation were applied according to the International Multiple Myeloma Working group (IMWG) guidelines.
Results: This study was carried on 20 patients, the age of the studied patients ranged from 42 to 69, and most of them were males. CRBN ranged from 2.4 to 3.9 with mean of 3.1. All patients were CMV, HIV, HBV negative and 15% of them had HCV positive. In our study when comparing the CBC results between 3 and 6 months after treatment, there is statistically significant increase in Hb, and Platelet; while the other CBC results showed no statistically significant difference.
Conclusion: Although few studies reported a correlation between high CRBN expression and achievement of a favorable treatment response (CR, VGPR, PR) but without a significant association between CRBN expression and PFS or OS, in our study we couldn’t prove or deny that CRBN can be used as a reliable prognostic marker and this may be due to the limited number of studied patients as a Pilot study.